Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 15 Dec 2012

Lam Jerika T, Jacob Susan

Abstract excerpt

PURPOSE: The pharmacologic properties, clinical efficacy, and safety profile of the first oral protease inhibitor approved for the treatment of chronic infection with hepatitis C virus (HCV) genotype 1 are reviewed. SUMMARY: Boceprevir, approved by the Food and Drug Administration as an adjunct to the standard regimen for HCV genotype 1 infection (peginterferon alfa and ribavirin), is available in 200-mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Drug Interactions

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Proline

Share to Protease Inhibitors

Source

Identifiers

PMID: 23230035
DOI: 10.2146/ajhp110500

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.PMID 23230035Read ↗

Boceprevir: a protease inhibitor for the treatment of hepatitis C.Semantic proximity Read ↗

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.Semantic proximity Read ↗

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.Semantic proximity Read ↗

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.Semantic proximity Read ↗

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.Semantic proximity Read ↗

[New agents for the treatment of hepatitis C].Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Semantic proximity Read ↗

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.Semantic proximity Read ↗

Boceprevir for previously treated chronic HCV genotype 1 infection.Semantic proximity Read ↗

Advances in the management of hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.